Background Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in
foetal life. Researchers have recently attempted to use anti‐VEGF agents for the treatment of …

Retinopathy of prematurity (ROP) occurs because the retina of a preterm infant at birth is
incompletely vascularized, and if the postnatal environment does not match the in utero …

Background Retinopathy of prematurity is a leading cause of childhood blindness
worldwide. Peripheral retinal ablation with conventional (confluent) laser therapy is …

The Epidemiology of Retinopathy of Prematurity in the United States Page 1 ■
CLINICALSCIENCE ■ July 2017 · Vol. 48, No. 7 553 The Epidemiology of Retinopathy of …

Purpose.: To measure serum levels of bevacizumab and to compare serum levels of free
vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in infants …

PURPOSE: To investigate the effects and complications of the anti-vascular endothelial
growth factor agent bevacizumab in the treatment of retinopathy of prematurity (ROP) in …

PURPOSE: To investigate the effectiveness and complications associated with the use of
bevacizumab, an anti–vascular endothelial growth factor agent, in the treatment of …

Retinopathy of prematurity (ROP), a retinal vascular disease of premature infants, continues
to be a major cause of preventable childhood blindness all over the world. The incidence of …

PURPOSE: To examine the quality of evidence and the variability in the off-label use of
bevacizumab (Avastin; Genentech Inc, South San Francisco, California, USA) in the …

The publication of the BEAT-ROP study of bevacizumab (Avastin) treatment for Zone I and II
retinopathy of prematurity (ROP) has raised hopes that there might now be a simpler …